Navigation Links
Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
Date:11/10/2008

AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects

ATLANTA, Nov. 10 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA. The data was from the ASaP (Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration) clinical trial for the company's leading drug candidate, POT-4, which is being developed for the treatment of AMD.

The ASaP trial is a first-in-man, multi-center, single escalating dose study. The interim results of this trial revealed no drug-related toxicity based on clinical signs, ophthalmic examinations, or laboratory results at any time point monitored in patients treated with up to 150 microgram/dose of POT- 4. Additionally, no serious adverse events and no identifiable intraocular inflammation were reported.

Preliminary results indicate that intravitreal POT-4 is safe, and the data accumulated so far support the continued investigation of POT-4 for the treatment of both dry and wet AMD with larger randomized clinical trials to further define its efficacy profile.

"These safety data strongly support the further development of POT-4 as a potential treatment for patients with AMD," said Cedric Francois, President and CEO of Potentia Pharmaceuticals. "We believe that the product has significant promise based on these early-stage findings and look forward to further testing of the compound in higher doses as we continue this trial."

About POT-4

POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF) in the eye.
'/>"/>

SOURCE Potentia Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Discovery of creator gene for cerebral cortex points to potential stem cell treatments
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., SHANGHAI, Nov. 9 /PRNewswire-Asia/ -- The p...n their evolution. The companies are facing signi... skyrocketing R&D costs, calls for,lower price...s together with,the financial crisis have made the...pharmaceutical companies are being forced to globa...
(Date:11/9/2009)..., VIENNA, Va., Nov. 9 C...day that Dr. Kenneth S. Rosenthal, Professor of Im...versities College of Medicine and Pharmacy, report...sts at the Cleveland Clinic and CEL-SCI on CEL-SCI...ed at the 7th GTCbio Vaccine: "All Things Consider...
(Date:11/9/2009)... Product release is a resear...bjects, research facilities and research safety st.... , Cedar Knolls, NJ (PRW...ounced today that it has unveiled Pristima™ ... research facilities that track the use and care o...
(Date:11/8/2009)...ovember 6, 2009 As global temperatures and energy...gy will be key to a sustainable future. An attra...two studies published online in Genome Research ...enome structures of bioethanol-producing microorga...cal in developing new technologies needed to imple...
Breaking Biology Technology:Pharma and Biotech Leaders to Converge in Shanghai 2CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 2CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 3Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2
...s Pharma, the,Danish biopharmaceutical company dev...at Keith McCullagh, President and Chief Executive,...pany and its goals for,2008 at the Biotechnology I...Conference in New York, today, Monday February 11t...ral European Time). The conference is,being held a...
...28, The Royal,Marsden Hospital (Sutton, Surrey, UK...lated Arc Therapy (VMAT)* treatment in the world u...e the treatment, the hospital,used its existing El...n,linear accelerator control system., (Logo: htt...GO ), VMAT takes Intensity Modulated Radiation T...
...0 Doses of the CDC,s National Strategic...OLIS, Feb. 11 Sentry Logistic Solutions,announced...ention (CDC),signed a contract to outsource storag...ve of the influenza virus vaccine. Sentry will war...ses from its pharmaceutical cold,chain logistics c...
Other Biology Technology:Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008 2Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions 2The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions 3
(Date:11/5/2009)...hers (NABT) will recognize Leonard C. Yannielli, p...y Community College (NVCC) in Waterbury, Connectic... the NABT annual professional development conferen...ado. , The Evolution Education Award is cosponso...es,(AIBS) and Biological Sciences Curriculum Stud...
(Date:11/4/2009)...luctant to officially endorse green tea as a cance...out its protective effects, including results of a...h , a journal of the American Association for Canc... cancer. , Vassiliki Papadimitrakopoulo, M.D., ...c/Head and Neck Medical Oncology at the University...
(Date:11/4/2009)...od obesity in the United States is reaching epidem...tising on daytime and prime time television devote...about the role television plays in obesity, a stud...f Nutrition Education and Behavior examines how f... contributor to the problem. , Researchers at th...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 1Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 2Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 3VIVUS Reports Second Quarter 2009 Financial Results 54258 1VIVUS Reports Second Quarter 2009 Financial Results 54258 2VIVUS Reports Second Quarter 2009 Financial Results 54258 3VIVUS Reports Second Quarter 2009 Financial Results 54258 4VIVUS Reports Second Quarter 2009 Financial Results 54258 5VIVUS Reports Second Quarter 2009 Financial Results 54258 6VIVUS Reports Second Quarter 2009 Financial Results 54258 7Ohio Judge Rules Tobacco Settlement Funds Should Be Used as Intended to Reduce Tobacco Use and Save Lives 54255 1Ohio Judge Rules Tobacco Settlement Funds Should Be Used as Intended to Reduce Tobacco Use and Save Lives 54255 2
...r gene has been discovered by scientists at the Lu...tic Surgery Clinic at the Sahlgrenska Academy in S...tain hereditary deformity syndrome run a nearly tw...r than expected. , Several research teams around ...ary breast cancer genes, but thus far few have bee...
...ng Project, funded by the National Institute of Al...National Institutes of Health (NIH), announced tod...ire genetic blueprints of more than 2,000 human an...d the world have been completed and the sequence d...information will help scientists understand how in...
...of York have won a grant of £110,000 to investigat...sease. , Dr Jason Lynam and Dr Ian Fairlamb, of t... awarded the funding by the Leverhulme Trust for a...for the controlled release of carbon monoxide into...inflammatory, and they want to explore its potenti...
Other Biology News:New hereditary breast cancer gene discovered 22,000 influenza virus genomes now completed and publicly accessible 2Research to spotlight carbon monoxide benefits 2
GIBCO Improved MEM Zn++ Option (Richter's Modification) liquid from Invitrogen
GIBCO AlbuMAX I from Invitrogen
Chicken Anti-EEA1 Monoclonal Antibody, Unconjugated, Clone PADZMD.477 from Invitrogen
GIBCO Chemically Defined Lipid Concentrate from Invitrogen
Biology Products: